Edoxaban effective in preventing stroke, reducing bleeding and cardiovascular death in patients with atrial fibrillation

19-11-2013 EurekAlert!Comments (0)

edoxabanPharmaceutical

(Brigham and Women's Hospital) A late-breaking clinical trial to be presented at the American Heart Association Scientific Sessions on Nov. 19, 2013, and published simultaneously online in the New England Journal of Medicine, demonstrates that high- and low-dose edoxaban were at least as effective in preventing stroke or systemic embolism (blood clot), while significantly reducing bleeding and cardiovascular death, compared to warfarin.

Read more on EurekAlert!

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top